Dr. Alan Skarbnik, MD
Claim this profileNovant Health Presbyterian Medical Center
Studies Lymphoma
Studies Chronic B-Cell Leukemia
8 reported clinical trials
16 drugs studied
Area of expertise
1Lymphoma
Stage IV
Stage III
CCND1 positive
2Chronic B-Cell Leukemia
Affiliated Hospitals
Clinical Trials Alan Skarbnik, MD is currently running
Pirtobrutinib + VR
for Chronic Lymphocytic Leukemia
The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm B) in patients with CLL/SLL who have been previously treated with at least one prior line of therapy. Participation could last up to five years.
Recruiting2 awards Phase 3
Rituximab + Stem Cell Transplant
for Mantle Cell Lymphoma
This randomized phase III trial studies rituximab after stem cell transplant and to see how well it works compared with rituximab alone in treating patients with in minimal residual disease-negative mantle cell lymphoma in first complete remission. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Giving chemotherapy before a stem cell transplant helps kill any cancer cells that are in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. After treatment, stem cells are collected from the patient's blood and stored. More chemotherapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. Giving rituximab with or without stem cell transplant may work better in treating patients with mantle cell lymphoma.
Recruiting2 awards Phase 3
More about Alan Skarbnik, MD
Clinical Trial Related5 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Alan Skarbnik, MD has experience with
- Pirtobrutinib
- Rituximab
- Cyclophosphamide
- Fludarabine
- JCAR017
- ClonoSEQ Assay
Breakdown of trials Alan Skarbnik, MD has run
Lymphoma
Chronic B-Cell Leukemia
Chronic Lymphocytic Leukemia
Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Alan Skarbnik, MD specialize in?
Alan Skarbnik, MD focuses on Lymphoma and Chronic B-Cell Leukemia. In particular, much of their work with Lymphoma has involved Stage IV patients, or patients who are Stage III.
Is Alan Skarbnik, MD currently recruiting for clinical trials?
Yes, Alan Skarbnik, MD is currently recruiting for 2 clinical trials in Charlotte North Carolina. If you're interested in participating, you should apply.
Are there any treatments that Alan Skarbnik, MD has studied deeply?
Yes, Alan Skarbnik, MD has studied treatments such as Pirtobrutinib, Rituximab, Cyclophosphamide.
What is the best way to schedule an appointment with Alan Skarbnik, MD?
Apply for one of the trials that Alan Skarbnik, MD is conducting.
What is the office address of Alan Skarbnik, MD?
The office of Alan Skarbnik, MD is located at: Novant Health Presbyterian Medical Center, Charlotte, North Carolina 28204 United States. This is the address for their practice at the Novant Health Presbyterian Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.